NBIO (Nascent Biotech) Beta: 6.3548 (As of Jun. 26, 2026)


What is Nascent Biotech Beta?

Nascent Biotech NBIO +66.67% Beta is 6.3548 as of Jun. 26, 2026.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), Nascent Biotech's Beta is 6.3548.

Nascent Biotech  (OTCPK:NBIO) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Nascent Biotech Beta Related Terms

Nascent Biotech Beta Historical Data

* Premium members only.

The historical data trend for Nascent Biotech's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nascent Biotech Beta Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Beta
Get a 7-Day Free Trial -2.37 -2.79 -2.28 -3.46 -3.14

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.21 -3.65 -3.46 -3.14 -2.95

NBIO vs BTAX, PXMD, XSNX: Beta Comparison

For the Biotechnology subindustry, Nascent Biotech's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nascent Biotech Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Beta distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Beta falls into.


Nascent Biotech Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 6.3548 mean?
Nascent Biotech (NBIO) has a Beta of 6.3548 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Nascent Biotech and its competitors.
Is Nascent Biotech's Beta too high?
Nascent Biotech's current Beta is 6.3548.
How does Nascent Biotech's Beta compare to BTAX and PXMD?
Nascent Biotech's Beta of 6.3548 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Nascent Biotech and its competitors. Nascent Biotech's current Beta is 6.3548. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Biotech stock overvalued right now?
Nascent Biotech (NBIO) has a current Beta of 6.3548. The current Beta is 6.3548. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Nascent Biotech (NBIO), the current Beta is 6.3548 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nascent Biotech Business Description

Address 631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.